Genervon Biopharmaceuticals LLC (“Genervon”) today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis (“ALS”) disease modification. A full analysis of the trial’s results is expected to be completed in the…
Source:Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis
Monday, April 28, 2014
Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment